ProQR Therapeutics N.V. PRQR
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 35.17% | -50.80% | 19.30% | 6.91% | -30.32% |
| Total Depreciation and Amortization | 1.27% | 2.73% | 0.75% | 2.40% | 7.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.25% | 8.69% | 12.55% | -5.59% | 326.33% |
| Change in Net Operating Assets | -5,348.94% | 101.70% | -108.70% | -168.82% | 81.10% |
| Cash from Operations | -9.44% | 16.14% | -8.70% | -10.55% | 22.17% |
| Capital Expenditure | -76.39% | 68.66% | -209.87% | -72.43% | 51.38% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -76.39% | 68.66% | -209.87% | -72.43% | 51.38% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -104.28% | 49.42% | -35.36% | -51.54% | 48.32% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 15,984.85% | 48.99% | -34.33% | -56.12% | 36.81% |
| Foreign Exchange rate Adjustments | -93.80% | 2,307.14% | 135.18% | 95.89% | -95.13% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 416.32% | 21.34% | -11.85% | -4.91% | 19.73% |